- Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer“In truth, I don’t anticipate prescribing patterns changing immediately,” cardiologist Vishal Khetpal writes of the new cholesterol drug Lipfendra.STAT · 5d ago↗ source
- STAT+: Federal health quality research grants worth $109 million ended earlyAt least 78 AHRQ grants worth $200 million have been affected by "non-award" notices; it's estimated those grants had $109.2 million in funding remaining.STAT · 5d ago↗ source
- From Big Pharma to specialty: why moving closer to the patient changes everythingWorking at a Big Pharma has its benefits, but there are limitations too. SERB Pharmaceuticals’ Thomas Kolaras discusses how moving to a midsize company creates new opportunities for sharpened think…